コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ) and CD45-reconstituted (CD45+) J558L mu m3 plasmacytoma.
2 glycoprotein), was recently isolated from a plasmacytoma.
3 ng smouldering multiple myeloma and solitary plasmacytoma.
4 ies to subsets of human multiple myeloma and plasmacytoma.
5 in human endemic Burkitt lymphoma and mouse plasmacytoma.
6 igh-grade angiogenesis was present in 64% of plasmacytomas.
7 d and significantly suppressed the growth of plasmacytomas.
8 d the function of this enhancer in mammalian plasmacytomas.
9 ecursor clones into Igh alpha/c-myc-positive plasmacytomas.
10 o reflect the general genomic instability of plasmacytomas.
11 l translocations in t(12;15)-positive BALB/c plasmacytomas.
12 ry cytogenetic aberrations in primary BALB/c plasmacytomas.
13 ulated into BALB/c mice to produce growth of plasmacytomas.
14 nal A-type particle long terminal repeats in plasmacytomas.
15 , 4 cases of hairy cell leukemia (HCL) and 3 plasmacytomas.
16 pathway to confer IL6 independence on murine plasmacytomas.
17 sing an Emicro-v-abl oncogene solely develop plasmacytomas.
18 s, and macrophages not seen with plasmacytic plasmacytomas.
19 features of transgenic and pristane-induced plasmacytomas.
20 cation that deregulates Myc in certain mouse plasmacytomas.
21 vation of Myc in the great majority of mouse plasmacytomas.
22 ve mutant or a structural homolog, protected plasmacytomas against IL6 withdrawal-induced apoptosis a
23 s affecting c-myc occur in almost all murine plasmacytoma and human Burkitt's lymphoma tumors and are
24 ned if angiogenesis is increased in solitary plasmacytoma and if it can help identify patients likely
29 adioimmunotherapy (RIT) in the management of plasmacytomas and multiple myeloma has undergone only li
30 dominantly develop late stage B cell tumors (plasmacytomas) and less frequently develop earlier B-lin
32 tin superfamily of adhesion molecules, Pang (plasmacytoma-associated neuronal glycoprotein), was rece
35 r studies reveal: (a) antibodies secreted by plasmacytomas bind to different antigens in a manner sim
37 lasms (PCNs, comprising multiple myeloma and plasmacytoma), but little is known about risk factors in
38 raise suspicion about associated lymphoma or plasmacytoma, but negative PET results do not exclude th
39 was observed in one of the IL-6-independent plasmacytomas, but not in others, making an autocrine me
40 kground of C increased the incidence of GALT plasmacytomas by a factor of 2.5 in first-generation bac
41 st cell-derived Ang-1 promotes the growth of plasmacytomas by stimulating neovascularization and prov
42 eristic of Burkitt lymphomas (BL) and murine plasmacytomas, c-myc genes become juxtaposed to immunogl
45 activated endogenous mb-1 transcription in a plasmacytoma cell line, but could not when the promoter
46 ning the B29 octamer motif is expressed in a plasmacytoma cell line, while the wild-type mb-1 promote
49 unterpart in inducing growth arrest of mouse plasmacytoma cell lines and preventing ras-induced trans
50 cells accelerate tumor growth by established plasmacytoma cell lines and that neutralization of Ang-1
51 but not Ang-2 and that 2 established murine plasmacytoma cell lines express high levels of VEGF-A bu
52 f cell death in IL-6-starved T1165 and T1198 plasmacytoma cell lines is apoptosis, and that it can be
53 spond to this approach, we examined 3 murine plasmacytoma cell lines, 2 (MPC-11 and S107) expressing
58 tion that p28/CLF, unlike IL-27, sustains B9 plasmacytoma cell proliferation prompted us to investiga
59 e is evolutionarily conserved and exhibits a plasmacytoma cell-specific DNase I-hypersensitive site i
61 EBF1 and RUNX1 in terminally differentiated plasmacytoma cells activated multiple early B cell-speci
62 ve NF-kappaB activation, similarly protected plasmacytoma cells against IL6 withdrawal-induced apopto
63 gize with E47 inhibited enhancer activity in plasmacytoma cells and could not activate transcription
64 t XBP-1(S) binds to the promoter of ERdj3 in plasmacytoma cells and in LPS-stimulated primary splenic
65 romoter activity was up-regulated by BSAP in plasmacytoma cells and T cells in a dose-dependent manne
66 survival factors for malignant lymphoma and plasmacytoma cells derived from transgenic Emu-Myc mice
70 s Ang-1, and recombinant Ang-1 together with plasmacytoma cells promotes extracellular matrix neovasc
71 d, major histocompatibility complex-negative plasmacytoma cells to maturing mouse dendritic cells (DC
72 ression of a number of genes in AID-silenced plasmacytoma cells, and upregulation of CD200 was shown
73 dogenous early B-cell-specific mb-1 genes in plasmacytoma cells, but only when the promoter is hypome
74 Lysine 170 was acetylated in pre-B cells and plasmacytoma cells, but TSA treatment did not stimulate
75 istent inactivation of TGF-beta receptors in plasmacytoma cells, demonstrating for the first time tha
77 h received chambers containing untransfected plasmacytoma cells, secreted primarily IL-2 and IL-4, wi
78 matrix components shows that mast cells and plasmacytoma cells, together, promote marked neovascular
85 nd 3' RR elements in MPC11, which like other plasmacytomas contains a reciprocal translocation betwee
86 ted that the iMyc(Emu) transgene accelerates plasmacytoma development by collaborating with tumor sus
88 ns (oil granulomata) during pristane-induced plasmacytoma development in susceptible BALB/cAn mice.
90 at small interfering RNA silencing of AID in plasmacytoma dramatically increased its susceptibility t
91 lasmacytoma (SBP; n = 35) and extramedullary plasmacytoma (EMP; n = 29) through multiparameter flow c
92 y reduces kiss1 and serotonin-related genes (plasmacytoma expressed transcript 1 and solute carrier f
93 at the light chain level with at least three plasmacytomas expressing both kappa and lambda light cha
95 gene expression profiles of newly identified plasmacytomas from NFS.V(+) congenic mice with plasmacyt
96 emic Burkitt lymphoma-like translocations in plasmacytomas from uracil N-glycosylase and activation-i
98 f monoclonal immunoglobulin (Ig) produced by plasmacytomas have found no universally common binding p
101 ified, is a tumor rejection antigen for J558 plasmacytoma in mice with an unperturbed T-cell repertoi
105 ping (SKY) to evaluate 10 established BALB/c plasmacytomas in which the T(12;15) had been previously
106 ded by the Pctm locus, in which mouse B-cell plasmacytomas induced by pristane are associated with he
109 he genetic susceptibility of BALB/c mice for plasmacytoma induction and that p16(INK4a) is a strong c
112 lambdaLIZ N5 mice in the terminal stage of a plasmacytoma induction experiment, 213-280 days after th
116 ptibility of BALB/c mice to pristane-induced plasmacytomas is a complex genetic trait involving multi
117 step in the malignant progression of murine plasmacytomas is the transition from dependence on IL-6
118 tumor immunity, we generated IL-35-producing plasmacytoma J558 and B16 melanoma cells and observed th
119 ited into B7-1-transfected class II-negative plasmacytoma J558, and the virus-infected central nervou
122 ne mustard) to mice bearing a large MOPC-315 plasmacytoma led to a rapid up-regulation of B7-1 (CD80)
124 nds to the OBF-1/BOB-1/OCA-B promoter in the plasmacytoma line and in primary B cells not only during
126 RNA was used to decrease XBP-1 expression in plasmacytoma lines, ERdj3 transcripts were concomitantly
127 odels: human MM injected subcutaneously (the plasmacytoma model) and luciferase-expressing human MM i
128 r, despite some evidence obtained from mouse plasmacytoma models, it is still unclear whether Id-spec
129 es significant antitumor activity in a human plasmacytoma mouse model, associated with down-regulatio
133 lymphoma (n = 7), Burkitts lymphoma (n = 6), plasmacytoma (n = 5), and mucosa-associated lymphoid tis
135 location in all of these tumors and in three plasmacytomas newly identified secondary cytogenetic cha
137 rrow disease (OMD) in patients with solitary plasmacytoma of bone and assess its value in predicting
140 lated to immunoblastic lymphomas, less so to plasmacytomas of Fasl mutant and SJL mice, and least to
142 asmacytomas from NFS.V(+) congenic mice with plasmacytomas of IL6 transgenic, Fasl mutant, and SJL-be
144 tumors arose in peripheral lymphoid organs (plasmacytomas) or within the bone marrow and often led t
145 re-, and mature B-cell lines, but not in two plasmacytomas; Pax-5b was shown to be present at low lev
146 er (10 to 20 microg/mL) profoundly inhibited plasmacytoma (PCT) development initiated by three 0.2- o
147 lammation- and interleukin 6-dependent mouse plasmacytoma (PCT), is the premier model of cancer-assoc
149 -activating translocations characteristic of plasmacytomas (PCT), little is known about genetic facto
150 itical oncogenic event in the development of plasmacytomas (PCTs) although it is not sufficient for t
157 to confirm a suspected diagnosis of solitary plasmacytoma, provided that whole-body MRI is unable to
158 obulinemia, chronic lymphocytic leukemia, or plasmacytoma (relative risk of progression, 25.0, 2.4, 8
162 mphoid tissues, raising the possibility that plasmacytoma resistance genes may inhibit tumor developm
163 cations in normal and immunized mice of both plasmacytoma resistant and susceptible lineages in the a
166 Patients with high-grade angiogenesis in the plasmacytoma sample were more likely to progress to myel
168 BM evaluation of patients with solitary bone plasmacytoma (SBP; n = 35) and extramedullary plasmacyto
170 most cases of mantle cell lymphoma, HCL, and plasmacytoma show high levels of pRB in contrast to foll
172 by the most prevalent tumors, plasmablastic plasmacytomas, showed them to be most closely related to
174 r 1B and Chr 4C7-D2, are suspected to harbor plasmacytoma susceptibility loci; Pctr1 and Pctr2 on Chr
175 ound to be increased approximately 3-fold in plasmacytoma-susceptible BALB/c and C.D2-Idh1-Pep3 mice,
176 s were detected in as many as 73% (32/44) of plasmacytoma-susceptible BALB/cAn mice 30 days after an
178 range, 3.1-6.7) and 1 patient with a pleural plasmacytoma (SUVmax, 7.2); the remaining 3 patients had
181 558L HI, an interleukin 5-transfected murine plasmacytoma that is infiltrated by numerous degranulati
182 15) found in a subset (approximately 20%) of plasmacytomas that develop "spontaneously" in the gut-as
184 However, the kappaB binding complex in the plasmacytomas that were examined lacked c-Rel and instea
185 We have thus examined the ability of murine plasmacytoma to produce disseminated growth similar to t
186 Diffusion chambers injected with X63.Ag-653 plasmacytoma transfectants that constitutively produce r
187 sceptible to inflammation-induced peritoneal plasmacytomas (tumor incidence, 100%; mean tumor onset,
188 ells (IC(50) < 100 nM), inhibits xenografted plasmacytoma tumors in mice, and is synergistically cyto
191 ntibodies secreted by silicone-induced mouse plasmacytomas using a broader panel of antigens includin
193 reported association between variants in the plasmacytoma variant translocation gene (PVT1) and ESRD
197 at typically occur in pristane-induced mouse plasmacytomas were detected in secondary lymphoid tissue
198 ch as Burkitt's lymphoma and t(12;15) BALB/c plasmacytomas, where most breakpoints are found near the
199 osphorylated in a subset of IL-6-independent plasmacytomas, whereas other IL-6-independent lines show
201 n binding properties, but instead, groups of plasmacytomas with specific antigen-binding activities t
202 tro in the absence of IL6 and form abdominal plasmacytomas with visceral involvement when injected in
203 diffuse large B-cell lymphomas, and CD138(+) plasmacytomas, with an overall incidence of 68% by 21 mo
204 silencing of B lymphocyte-specific genes in plasmacytoma x T lymphoma hybrids can be prevented by pr
205 his transcription factor on the phenotype of plasmacytoma x T lymphoma hybrids established a critical
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。